{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:31:46Z","timestamp":1793151106213,"version":"4.5.0"},"reference-count":398,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.575597","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T06:05:18Z","timestamp":1602741918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":426,"title":["Localized Interleukin-12 for Cancer Immunotherapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Khue G.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura R.","family":"Vrabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena M.","family":"Mantooth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared J.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor A.","family":"Gabaldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Zaharoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1084\/jem.98.5.493","article-title":"Studies on the pathogenesis of fever. II. Characterization of fever-producing substances from polymorphonuclear leukocytes and from the fluid of sterile exudates","volume":"98","author":"Bennett","year":"1953","journal-title":"J Exp Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin Oncol."},{"key":"B3","first-page":"7","article-title":"Melanoma: therapeutic options with recombinant interferons","volume":"12","author":"Kirkwood","year":"1985","journal-title":"Semin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and (1993)","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1073\/pnas.88.10.4143","article-title":"Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor","volume":"88","author":"Gubler","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med."},{"key":"B9","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.4049\/jimmunol.146.9.3074","article-title":"Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells","volume":"146","author":"Wolf","year":"1991","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.4049\/jimmunol.148.11.3433","article-title":"Cloning and expression of murine IL-12","volume":"148","author":"Schoenhaut","year":"1992","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.4049\/jimmunol.178.3.1357","article-title":"IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo","volume":"178","author":"Watkins","year":"2007","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2567.2011.03429.x","article-title":"The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis","volume":"133","author":"Steding","year":"2011","journal-title":"Immunology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1084\/jem.2045fta","article-title":"Interleukin-12: a master regulator","volume":"204","author":"Bashyam","year":"2007","journal-title":"J Exp Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1259050","DOI":"10.1080\/2162402X.2016.1259050","article-title":"Immunological mechanisms of intravesical chitosan\/interleukin-12 immunotherapy against murine bladder cancer","volume":"6","author":"Smith","year":"2017","journal-title":"Oncoimmunology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e46241","DOI":"10.1371\/journal.pone.0046241","article-title":"Differential effects of IL-12 on tregs and non-Treg T cells: roles of IFN-gamma, IL-2 and IL-2R","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS ONE."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors","volume":"121","author":"Kerkar","year":"2011","journal-title":"J Clin Invest."},{"key":"B17","first-page":"735","article-title":"Antiproliferative effects of four different cytokines on renal carcinoma cell lines","volume":"15","author":"Buszello","year":"1995","journal-title":"Anticancer Res."},{"key":"B18","first-page":"2487","article-title":"IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro","volume":"9","author":"Wall","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jnci\/87.8.581","article-title":"Inhibition of angiogenesis in vivo by interleukin 12","volume":"87","author":"Voest","year":"1995","journal-title":"J Natl Cancer Inst."},{"key":"B20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ijc.2910510422","article-title":"Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60)","volume":"51","author":"Saiki","year":"1992","journal-title":"Int J Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/CJI.0b013e3181eb826d","article-title":"Intratumoral immunotherapy of established solid tumors with chitosan\/IL-12","volume":"33","author":"Zaharoff","year":"2010","journal-title":"J Immunother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"11798","DOI":"10.1073\/pnas.93.21.11798","article-title":"Effect of interleukin 12 on tumor induction by 3-methylcholanthrene","volume":"93","author":"Noguchi","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/bjc.1998.105","article-title":"Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity","volume":"77","author":"Vizler","year":"1998","journal-title":"Br J Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.4049\/jimmunol.165.5.2665","article-title":"The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent","volume":"165","author":"Smyth","year":"2000","journal-title":"J Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J Exp Med."},{"key":"B28","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res."},{"key":"B29","first-page":"75","article-title":"Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma","volume":"4","author":"Bajetta","year":"1998","journal-title":"Clin Cancer Res."},{"key":"B30","first-page":"1183","article-title":"Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma","volume":"4","author":"Motzer","year":"1998","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood."},{"key":"B32","first-page":"3686","article-title":"Phase I study of intraperitoneal recombinant human interleukin 12 in patients with mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma","volume":"8","author":"Lenzi","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00002371-200307000-00006","article-title":"Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder","volume":"26","author":"Weiss","year":"2003","journal-title":"J Immunother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ygyno.2003.12.022","article-title":"A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern cooperative oncology group study E1E96","volume":"92","author":"Wadler","year":"2004","journal-title":"Gynecol Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ijc.11696","article-title":"NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation","volume":"109","author":"Xu","year":"2004","journal-title":"Int J Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1158\/1078-0432.CCR-04-1524","article-title":"Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor","volume":"11","author":"van Herpen","year":"2005","journal-title":"Clin Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1182\/blood-2005-11-4455","article-title":"Activity of subcutaneous interleukin-12 in AIDS-related kaposi sarcoma","volume":"107","author":"Little","year":"2006","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1158\/1078-0432.CCR-04-0540","article-title":"Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-hodgkin's lymphoma and hodgkin's disease","volume":"10","author":"Younes","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B39","first-page":"3559","article-title":"Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12","volume":"60","author":"Mortarini","year":"2000","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/jnci\/88.9.576","article-title":"After initial setback, IL-12 regaining popularity","volume":"88","author":"Jenks","year":"1996","journal-title":"J Natl Cancer Inst."},{"key":"B41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol Immunother."},{"key":"B42","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/gyno.2001.6255","article-title":"Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study","volume":"82","author":"Hurteau","year":"2001","journal-title":"Gynecol Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/107999001750169934","article-title":"Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma","volume":"21","author":"Motzer","year":"2001","journal-title":"J Interferon Cytokine Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1172\/JCI5028","article-title":"Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal","volume":"103","author":"Benjamin","year":"1999","journal-title":"J Clin Invest."},{"key":"B46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11307-016-1010-5","article-title":"Patterns of vasculature in mouse models of lung cancer are dependent on location","volume":"19","author":"Vilalta","year":"2017","journal-title":"Mol Imaging Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1089\/hum.1996.7.16-1995","article-title":"Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12","volume":"7","author":"Bramson","year":"1996","journal-title":"Hum Gene Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00262-012-1248-y","article-title":"Co-delivery of antigen and IL-12 by venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects","volume":"61","author":"Osada","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-18-2819","article-title":"Right time and place for IL12: targeted delivery stimulates immune therapy","volume":"25","author":"Lyerly","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"key":"B51","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2174\/156652305774964712","article-title":"Gene therapy of cancer based on interleukin 12","volume":"5","author":"Sangro","year":"2005","journal-title":"Curr Gene Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e968001","DOI":"10.4161\/21624011.2014.968001","article-title":"Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis","volume":"3","author":"Vo","year":"2014","journal-title":"Oncoimmunology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-015-1672-x","article-title":"Intravesical chitosan\/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer","volume":"64","author":"Smith","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41434-018-0044-5","article-title":"Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy","volume":"26","author":"Mukhopadhyay","year":"2019","journal-title":"Gene Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/jso.20572","article-title":"Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity","volume":"94","author":"Arora","year":"2006","journal-title":"J Surg Oncol."},{"key":"B56","first-page":"76","article-title":"Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses","volume":"9","author":"Portielje","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","article-title":"Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma","volume":"93","author":"Bromberg","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.4049\/jimmunol.177.5.3004","article-title":"IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor","volume":"177","author":"Hollenbaugh","year":"2006","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","article-title":"IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer","volume":"28","author":"Martini","year":"2010","journal-title":"Vaccine."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1182\/blood.V100.5.1728.h81702001728_1728_1733","article-title":"IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide","volume":"100","author":"Hayakawa","year":"2002","journal-title":"Blood."},{"key":"B61","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/eji.1830160709","article-title":"Interferon: a cytotoxic T lymphocyte differentiation signal","volume":"16","author":"Chen","year":"1986","journal-title":"Eur J Immunol."},{"key":"B62","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4049\/jimmunol.143.4.1210","article-title":"IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells","volume":"143","author":"Maraskovsky","year":"1989","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.164.6.2113","article-title":"Gamma interferon enhances macrophage transcription of the tumor necrosis factor\/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors","volume":"164","author":"Collart","year":"1986","journal-title":"J Exp Med."},{"key":"B64","first-page":"47","article-title":"Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation?","volume":"7","author":"Rosa","year":"1986","journal-title":"Interferon."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature."},{"key":"B68","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr Opin Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"6962","DOI":"10.4049\/jimmunol.177.10.6962","article-title":"Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector\/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors","volume":"177","author":"Kilinc","year":"2006","journal-title":"J Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.4049\/jimmunol.172.5.2818","article-title":"IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells","volume":"172","author":"Chang","year":"2004","journal-title":"J Immunol."},{"key":"B72","first-page":"882","article-title":"Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory","volume":"1","author":"Diaz-Montero","year":"2011","journal-title":"Am J Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jamcollsurg.2011.12.034","article-title":"Ex vivo interleukin-12-priming during CD8+ T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host","volume":"214","author":"Rubinstein","year":"2012","journal-title":"J Am Coll Surg."},{"key":"B74","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00262-018-2280-3","article-title":"Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-gamma","volume":"68","author":"Lin","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4049\/jimmunol.1300652","article-title":"Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control","volume":"191","author":"Gerner","year":"2013","journal-title":"J Immunol."},{"key":"B76","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.157.5.1935","article-title":"Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor","volume":"157","author":"Novelli","year":"1996","journal-title":"J Immunol."},{"key":"B77","unstructured":"Key words used for searching included IL-12, interleukin-12, cancer, tumor"},{"key":"B78","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.4049\/jimmunol.160.12.6195","article-title":"Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases","volume":"160","author":"Gillies","year":"1998","journal-title":"J Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-002-0302-6","article-title":"Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer","volume":"51","author":"Gillies","year":"2002","journal-title":"Cancer Immunol Immunother."},{"key":"B80","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4049\/jimmunol.163.1.250","article-title":"A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity","volume":"163","author":"Peng","year":"1999","journal-title":"J Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/107999001753124444","article-title":"Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12","volume":"21","author":"Peng","year":"2001","journal-title":"J Interferon Cytokine Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-05-0488","article-title":"Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2\/neu expressing tumors","volume":"5","author":"Helguera","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00262-007-0297-0","article-title":"Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies","volume":"56","author":"Helguera","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cyto.2019.04.004","article-title":"Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein","volume":"120","author":"Luria-Perez","year":"2019","journal-title":"Cytokine."},{"key":"B85","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1038\/s41598-017-05382-1","article-title":"Modulation of interleukin-12 activity in the presence of heparin","volume":"7","author":"Jayanthi","year":"2017","journal-title":"Sci Rep."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1074\/jbc.RA118.006193","article-title":"Molecular mechanisms of heparin-induced modulation of human interleukin 12 bioactivity","volume":"294","author":"Nguyen","year":"2019","journal-title":"J Biol Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"lb334","DOI":"10.1096\/fasebj.2019.33.1_supplement.lb334","article-title":"Species-specific differences in heparin-induced modulation of IL-12 family cytokines","volume":"33","author":"Nguyen","year":"2019","journal-title":"FASEB J."},{"key":"B88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pep.2014.07.002","article-title":"Efficient production and purification of recombinant human interleukin-12 (IL-12) overexpressed in mammalian cells without affinity tag","volume":"102","author":"Jayanthi","year":"2014","journal-title":"Protein Expr Purif."},{"key":"B89","unstructured":"NguyenKG Ann Arbor, MIThe University of North Carolina at Chapel HillEffect of heparin on the immunobiology of interleukin 122018"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e81919","DOI":"10.1371\/journal.pone.0081919","article-title":"Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS ONE."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3892\/ijo.2015.3115","article-title":"Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9","volume":"47","author":"Ji","year":"2015","journal-title":"Int J Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12032-015-0586-y","article-title":"Construction, expression, and function of 6B11ScFv-mIL-12, a fusion protein that attacks human ovarian carcinoma","volume":"32","author":"Cheng","year":"2015","journal-title":"Med Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e44482","DOI":"10.1371\/journal.pone.0044482","article-title":"An IL12-IL2-antibody fusion protein targeting hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack","volume":"7","author":"Jahn","year":"2012","journal-title":"PLoS ONE."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1097\/00005537-200307000-00023","article-title":"Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors","volume":"113","author":"Birchler","year":"2003","journal-title":"Laryngoscope."},{"key":"B95","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00262-006-0203-1","article-title":"huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models","volume":"56","author":"Lo","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-10-2490","article-title":"A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma","volume":"17","author":"Rudman","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B97","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/ijc.22101","article-title":"An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties","volume":"119","author":"Gafner","year":"2006","journal-title":"Int J Cancer."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood.V99.5.1659","article-title":"Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix","volume":"99","author":"Carnemolla","year":"2002","journal-title":"Blood."},{"key":"B100","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ijc.20952","article-title":"Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy","volume":"116","author":"Ebbinghaus","year":"2005","journal-title":"Int J Cancer."},{"key":"B101","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nbt0302-264","article-title":"Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature","volume":"20","author":"Halin","year":"2002","journal-title":"Nat Biotechnol."},{"key":"B102","first-page":"3202","article-title":"Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha","volume":"63","author":"Halin","year":"2003","journal-title":"Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"eaaw2614","DOI":"10.1126\/scitranslmed.aaw2614","article-title":"Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy","volume":"11","author":"Momin","year":"2019","journal-title":"Sci Transl Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat Biomed Eng."},{"key":"B105","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.1158\/1078-0432.CCR-11-1203","article-title":"A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma","volume":"17","author":"Eigentler","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"18139","DOI":"10.1074\/jbc.M116.737734","article-title":"Targeted reconstitution of cytokine activity upon antigen binding using split cytokine antibody fusion proteins","volume":"291","author":"Venetz","year":"2016","journal-title":"J Biol Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/cbr.1998.13.255","article-title":"A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors","volume":"13","author":"Hornick","year":"1998","journal-title":"Cancer Biother Radiopharm."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget."},{"key":"B109","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/15368590152740707","article-title":"Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors","volume":"20","author":"Sharifi","year":"2001","journal-title":"Hybrid Hybridomics."},{"key":"B110","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40425-019-0620-2","article-title":"Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12","volume":"7","author":"Morillon","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B111","doi-asserted-by":"publisher","first-page":"20558","DOI":"10.18632\/oncotarget.16137","article-title":"Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody","volume":"8","author":"Fallon","year":"2017","journal-title":"Oncotarget."},{"key":"B112","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-17-0483","article-title":"Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models","volume":"23","author":"Xu","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e1014760","DOI":"10.1080\/2162402X.2015.1014760","article-title":"Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation","volume":"4","author":"Schilbach","year":"2015","journal-title":"Oncoimmunology."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e1323161","DOI":"10.1080\/2162402X.2017.1323161","article-title":"Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo","volume":"6","author":"Eckert","year":"2017","journal-title":"Oncoimmunology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00262-016-1863-0","article-title":"Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models","volume":"65","author":"Eckert","year":"2016","journal-title":"Cancer Immunol Immunother."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e0129954","DOI":"10.1371\/journal.pone.0129954","article-title":"Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma","volume":"10","author":"Paoloni","year":"2015","journal-title":"PLoS ONE."},{"key":"B117","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1034\/j.1600-0625.2001.110306.x","article-title":"Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice","volume":"11","author":"Heinzerling","year":"2002","journal-title":"Exp Dermatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1024\/0036-7281\/a000262","article-title":"In vivo induction of interferon gamma expression in grey horses with metastatic melanoma resulting from direct injection of plasmid DNA coding for equine interleukin 12","volume":"153","author":"Muller","year":"2011","journal-title":"Schweiz Arch Tierheilkd."},{"key":"B121","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/hum.2005.16.35","article-title":"Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy","volume":"16","author":"Heinzerling","year":"2005","journal-title":"Hum Gene Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","article-title":"Intratumoral injection of IL-12 plasmid DNA\u2013results of a phase I\/IB clinical trial","volume":"14","author":"Mahvi","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"B123","first-page":"3281","article-title":"Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation","volume":"61","author":"Lohr","year":"2001","journal-title":"Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1006\/mthe.2002.0601","article-title":"IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma","volume":"5","author":"Lucas","year":"2002","journal-title":"Mol Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1089\/104454903322624966","article-title":"IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma","volume":"22","author":"Lucas","year":"2003","journal-title":"DNA Cell Biol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1158\/1078-0432.CCR-05-2727","article-title":"Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model","volume":"12","author":"Heller","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jnci\/94.10.762","article-title":"Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy","volume":"94","author":"Li","year":"2002","journal-title":"J Natl Cancer Inst."},{"key":"B128","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ymthe.2005.03.037","article-title":"Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer","volume":"12","author":"Li","year":"2005","journal-title":"Mol Ther."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1089\/104303401750270922","article-title":"Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer","volume":"12","author":"Tamura","year":"2001","journal-title":"Hum Gene Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2407-13-38","article-title":"Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma","volume":"13","author":"Sedlar","year":"2013","journal-title":"BMC Cancer."},{"key":"B131","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jgm.854","article-title":"In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas","volume":"8","author":"Shibata","year":"2006","journal-title":"J Gene Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.4161\/cbt.8.22.9734","article-title":"Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma","volume":"8","author":"Pavlin","year":"2009","journal-title":"Cancer Biol Ther."},{"key":"B133","first-page":"1005","article-title":"Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model","volume":"61","author":"Yamashita","year":"2001","journal-title":"Cancer Res."},{"key":"B134","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41434-018-0006-y","article-title":"Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters","volume":"25","author":"Burkart","year":"2018","journal-title":"Gene Ther."},{"key":"B135","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<400::AID-IJC13>3.0.CO;2-C","article-title":"Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state","volume":"75","author":"Harada","year":"1998","journal-title":"Int J Cancer."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00262-012-1214-8","article-title":"Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin\/granzyme-mediated and IFN-gamma-dependent manner: application of Trp2(180-188) peptides","volume":"61","author":"Sin","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B137","doi-asserted-by":"publisher","first-page":"5285890","DOI":"10.1155\/2017\/5285890","article-title":"Gene electrotransfer of plasmid-encoding IL-12 recruits the M1 Macrophages and antigen-presenting cells inducing the eradication of aggressive B16F10 murine melanoma","volume":"2017","author":"Lampreht Tratar","year":"2017","journal-title":"Mediators Inflamm."},{"key":"B138","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/cancers10120498","article-title":"IL-12 gene electrotransfer triggers a change in immune response within mouse tumors","volume":"10","author":"Shi","year":"2018","journal-title":"Cancers."},{"key":"B139","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s40425-019-0638-5","article-title":"Pre-clinical investigation of the synergy effect of interleukin-12 gene-electro-transfer during partially irreversible electropermeabilization against melanoma","volume":"7","author":"Pasquet","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/sj.gt.3301519","article-title":"In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice","volume":"8","author":"Kishida","year":"2001","journal-title":"Gene Ther."},{"key":"B141","first-page":"1173","article-title":"Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth","volume":"23","author":"Tamura","year":"2003","journal-title":"Anticancer Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1182\/blood.V96.4.1465","article-title":"Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction","volume":"96","author":"Carson","year":"2000","journal-title":"Blood."},{"key":"B143","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2478\/v10019-010-0041-9","article-title":"Electrogene therapy with interleukin-12 in canine mast cell tumors","volume":"45","author":"Pavlin","year":"2011","journal-title":"Radiol Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ijc.24418","article-title":"Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model","volume":"125","author":"Chuang","year":"2009","journal-title":"Int J Cancer."},{"key":"B145","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.rvsc.2018.11.001","article-title":"A combination of electrochemotherapy, gene electrotransfer of plasmid encoding canine IL-12 and cytoreductive surgery in the treatment of canine oral malignant melanoma","volume":"122","author":"Milevoj","year":"2019","journal-title":"Res Vet Sci."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/vco.12255","article-title":"Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer","volume":"15","author":"Cicchelero","year":"2017","journal-title":"Vet Comp Oncol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","article-title":"Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma","volume":"26","author":"Daud","year":"2008","journal-title":"J Clin Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/2326-6066.CIR-19-0359","article-title":"Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses","volume":"8","author":"Greaney","year":"2020","journal-title":"Cancer Immunol Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-19-0972","article-title":"Intratumoral delivery of plasmid IL12 via electroporation leads to regression of injected and noninjected tumors in merkel cell carcinoma","volume":"26","author":"Bhatia","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.biomaterials.2010.10.037","article-title":"Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration","volume":"32","author":"Tagalakis","year":"2011","journal-title":"Biomaterials."},{"key":"B152","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/0885328214551010","article-title":"Conjugation of poly(amidoamine) dendrimers with various acrylates for improved delivery of plasmid encoding interleukin-12 gene","volume":"29","author":"Sabahi","year":"2015","journal-title":"J Biomater Appl."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2217\/fon.13.82","article-title":"Preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells","volume":"9","author":"Hallaj-Nezhadi","year":"2013","journal-title":"Future Oncol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-0032-1331165","article-title":"Preparation and characterization of chitosan\/beta-cyclodextrin nanoparticles containing plasmid DNA encoding interleukin-12","volume":"63","author":"Nahaei","year":"2013","journal-title":"Drug Res."},{"key":"B155","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2217\/nnm.10.100","article-title":"Efficient gene delivery by EGF-lipoplexes in vitro and in vivo","volume":"6","author":"Bunuales","year":"2011","journal-title":"Nanomedicine"},{"key":"B156","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.msec.2016.07.066","article-title":"Polyethylenimine: a versatile, multifunctional non-viral vector for nucleic acid delivery","volume":"68","author":"Pandey","year":"2016","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"key":"B157","first-page":"3462","article-title":"Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases","volume":"9","author":"Jia","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B158","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.cgt.7700432","article-title":"Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector","volume":"9","author":"Jia","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"B159","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.colsurfb.2016.11.008","article-title":"Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene","volume":"150","author":"Sheikhsaran","year":"2017","journal-title":"Colloids Surf B Biointerfaces."},{"key":"B160","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12010-016-1991-1","article-title":"Enhanced delivery of plasmid encoding interleukin-12 gene by diethylene triamine penta-acetic acid (DTPA)-conjugated PEI nanoparticles","volume":"179","author":"Dehshahri","year":"2016","journal-title":"Appl Biochem Biotechnol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1080\/21691401.2016.1202256","article-title":"Delivery of plasmid encoding interleukin-12 gene into hepatocytes by conjugated polyethylenimine-based nanoparticles","volume":"45","author":"Khalvati","year":"2017","journal-title":"Artif Cells Nanomed Biotechnol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.gt.3300891","article-title":"Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity","volume":"6","author":"Mendiratta","year":"1999","journal-title":"Gene Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1089\/10430340050129477","article-title":"Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma","volume":"11","author":"Mendiratta","year":"2000","journal-title":"Hum Gene Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/sj.gt.3301766","article-title":"Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity","volume":"9","author":"Maheshwari","year":"2002","journal-title":"Gene Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/mthe.2000.0105","article-title":"Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment","volume":"2","author":"Maheshwari","year":"2000","journal-title":"Mol Ther."},{"key":"B166","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jgm.1273","article-title":"In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma","volume":"11","author":"Diez","year":"2009","journal-title":"J Gene Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.nano.2017.04.006","article-title":"Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer","volume":"13","author":"Liu","year":"2017","journal-title":"Nanomedicine."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1166\/jbn.2018.2593","article-title":"Local and systemic delivery of interleukin-12 gene by cationic micelles for cancer immunogene therapy","volume":"14","author":"Men","year":"2018","journal-title":"J Biomed Nanotechnol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1158\/1535-7163.MCT-05-0540","article-title":"Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB\/c mice bearing CT-26 carcinoma cells","volume":"5","author":"Kim","year":"2006","journal-title":"Mol Cancer Ther."},{"key":"B170","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1006\/mthe.2001.0425","article-title":"Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers","volume":"4","author":"Mahato","year":"2001","journal-title":"Mol Ther."},{"key":"B171","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0168-3659(02)00362-0","article-title":"Tumor regression by repeated intratumoral delivery of water soluble lipopolymers\/p2CMVmIL-12 complexes","volume":"87","author":"Yockman","year":"2003","journal-title":"J Control Release."},{"key":"B172","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ymthe.2004.03.015","article-title":"Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model","volume":"9","author":"Janat-Amsbury","year":"2004","journal-title":"Mol Ther."},{"key":"B173","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2004.08.015","article-title":"Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment","volume":"101","author":"Janat-Amsbury","year":"2005","journal-title":"J Control Release."},{"key":"B174","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.biomaterials.2018.11.027","article-title":"Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo","volume":"192","author":"Ji","year":"2019","journal-title":"Biomaterials"},{"key":"B175","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jconrel.2005.09.024","article-title":"Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer","volume":"109","author":"Fewell","year":"2005","journal-title":"J Control Release."},{"key":"B176","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CAD.0b013e3282f24017","article-title":"A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma","volume":"19","author":"Sonabend","year":"2008","journal-title":"Anticancer Drugs."},{"key":"B177","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/jgm.1356","article-title":"Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally","volume":"11","author":"Fewell","year":"2009","journal-title":"J Gene Med."},{"key":"B178","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/gt.2009.159","article-title":"Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer","volume":"17","author":"Anwer","year":"2010","journal-title":"Gene Ther."},{"key":"B179","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol Oncol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol Oncol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ygyno.2017.08.001","article-title":"A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: an NRG oncology\/gynecologic oncology group study","volume":"147","author":"Thaker","year":"2017","journal-title":"Gynecol Oncol."},{"key":"B182","first-page":"949","article-title":"Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model","volume":"1","author":"Shi","year":"2002","journal-title":"Mol Cancer Ther."},{"key":"B183","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1021\/acs.biomac.6b00433","article-title":"Cationic polyphosphazene vesicles for cancer immunotherapy by efficient in vivo cytokine IL-12 plasmid delivery","volume":"17","author":"Gao","year":"2016","journal-title":"Biomacromolecules."},{"key":"B184","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/cgt.2010.12","article-title":"Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome\/IL-12 pDNA complexes in mice","volume":"17","author":"Charoensit","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"B185","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1146\/annurev.nutr.24.012003.132407","article-title":"Retinoic acid receptors and cancers","volume":"24","author":"Soprano","year":"2004","journal-title":"Annu Rev Nutr."},{"key":"B186","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/sj.onc.1203547","article-title":"All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappaB, activated protein-1 and apoptosis in human lung cancer cells","volume":"19","author":"Manna","year":"2000","journal-title":"Oncogene."},{"key":"B187","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40425-018-0431-x","article-title":"Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma","volume":"6","author":"Lai","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B188","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1023\/a:1007582911958","article-title":"Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres","volume":"17","author":"Fu","year":"2000","journal-title":"Pharm Res."},{"key":"B189","unstructured":""},{"key":"B190","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1158\/1538-7445.AM2019-5017","article-title":"Abstract 5017: MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote T < sub>H < \/sub>1 transformation of the patient tumor microenvironment","volume":"79","author":"Luheshi","year":"2019","journal-title":"Cancer Res."},{"key":"B191","unstructured":""},{"key":"B192","doi-asserted-by":"publisher","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal Chem."},{"key":"B193","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tips.2007.05.005","article-title":"Viruses as anticancer drugs","volume":"28","author":"Russell","year":"2007","journal-title":"Trends Pharmacol Sci."},{"key":"B194","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"11302","DOI":"10.1073\/pnas.93.21.11302","article-title":"Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma","volume":"93","author":"Caruso","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B196","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/hum.1996.7.3-333","article-title":"Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12","volume":"7","author":"Bramson","year":"1996","journal-title":"Hum Gene Ther."},{"key":"B197","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1165\/ajrcmb.20.5.3412","article-title":"Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases","volume":"20","author":"Hirschowitz","year":"1999","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.cgt.7700061","article-title":"Construction and characterization of a recombinant adenoviral vector expressing human interleukin-12","volume":"6","author":"Qiao","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"B199","first-page":"3713","article-title":"Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases","volume":"6","author":"Worth","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbrc.2008.05.129","article-title":"Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor","volume":"372","author":"Kanagawa","year":"2008","journal-title":"Biochem Biophys Res Commun."},{"key":"B201","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/cgt.2011.78","article-title":"The antitumor effects of adenoviral-mediated, intratumoral delivery of interleukin 23 require endogenous IL-12","volume":"19","author":"Reay","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"B202","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cgt.7700013","article-title":"Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12","volume":"6","author":"Gambotto","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"B203","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/sj.cgt.7700072","article-title":"Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12","volume":"6","author":"Mazzolini","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"B204","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<813::AID-IJC24>3.0.CO;2-I","article-title":"Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma","volume":"81","author":"Pham-Nguyen","year":"1999","journal-title":"Int J Cancer."},{"key":"B205","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.gt.3300834","article-title":"Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model","volume":"6","author":"Nasu","year":"1999","journal-title":"Gene Ther."},{"key":"B206","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/0008-5472.CAN-06-3399","article-title":"Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors","volume":"67","author":"Raja Gabaglia","year":"2007","journal-title":"Cancer Res."},{"key":"B207","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cgt.2013.81","article-title":"Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma","volume":"21","author":"Thaci","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"B208","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cgt.7700399","article-title":"In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma","volume":"9","author":"Liu","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"B209","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4049\/jimmunol.159.1.351","article-title":"Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer","volume":"159","author":"Chen","year":"1997","journal-title":"J Immunol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.bbrc.2005.01.061","article-title":"A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma","volume":"328","author":"Gao","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"key":"B211","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/147323001003800326","article-title":"Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12","volume":"38","author":"Tian","year":"2010","journal-title":"J Int Med Res."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.gt.3302001","article-title":"Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model","volume":"10","author":"Nagayama","year":"2003","journal-title":"Gene Ther."},{"key":"B213","first-page":"6457","article-title":"Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells","volume":"60","author":"Andrews","year":"2000","journal-title":"Cancer Res."},{"key":"B214","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/jhep.2001.20796","article-title":"Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12","volume":"33","author":"Barajas","year":"2001","journal-title":"Hepatology."},{"key":"B215","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/sj.gt.3301617","article-title":"Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12","volume":"9","author":"Yamazaki","year":"2002","journal-title":"Gene Ther."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1210\/en.2002-221013","article-title":"Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12","volume":"144","author":"Zhang","year":"2003","journal-title":"Endocrinology."},{"key":"B217","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/sj.cgt.7700968","article-title":"Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant ewing's sarcoma","volume":"13","author":"Jia","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"B218","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0022-3468(99)90395-0","article-title":"Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12","volume":"34","author":"Davidoff","year":"1999","journal-title":"J Pediatr Surg."},{"key":"B219","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.162.1.609","article-title":"High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer","volume":"162","author":"Fernandez","year":"1999","journal-title":"J Immunol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1046\/j.1365-2265.2003.01915.x","article-title":"Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model","volume":"59","author":"Tanaka","year":"2003","journal-title":"Clin Endocrinol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/hum.2005.16.307","article-title":"Low-dose adenoviral immunotherapy of rat hepatocellular carcinoma using single-chain interleukin-12","volume":"16","author":"Waehler","year":"2005","journal-title":"Hum Gene Ther."},{"key":"B222","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/mt.2009.9","article-title":"Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters","volume":"17","author":"Bortolanza","year":"2009","journal-title":"Mol Ther."},{"key":"B223","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J Clin Oncol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/med.20127","article-title":"Membrane-tethered proteins for basic research, imaging, and therapy","volume":"28","author":"Cheng","year":"2008","journal-title":"Med Res Rev."},{"key":"B225","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4110\/in.2009.9.5.158","article-title":"Tumor therapy applying membrane-bound form of cytokines","volume":"9","author":"Kim","year":"2009","journal-title":"Immune Netw."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun."},{"key":"B227","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/mt.2012.10","article-title":"Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains","volume":"20","author":"Pan","year":"2012","journal-title":"Mol Ther."},{"key":"B228","first-page":"27","article-title":"The RheoSwitch system for inducible up- and down-regulation of gene expression","volume":"66","author":"Cress","year":"2006","journal-title":"Cancer Res."},{"key":"B229","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41417-018-0019-0","article-title":"Regulated intratumoral expression of IL-12 using a RheoSwitch therapeutic system((R)) (RTS((R))) gene switch as gene therapy for the treatment of glioma","volume":"25","author":"Barrett","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"B230","doi-asserted-by":"publisher","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med."},{"key":"B231","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/00000658-200005000-00017","article-title":"Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model","volume":"231","author":"Jarnagin","year":"2000","journal-title":"Ann Surg."},{"key":"B232","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.cgt.7700558","article-title":"Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection","volume":"10","author":"Jarnagin","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"B233","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/00000658-200106000-00012","article-title":"Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer","volume":"233","author":"Bennett","year":"2001","journal-title":"Ann Surg."},{"key":"B234","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1158\/1078-0432.CCR-04-0081","article-title":"Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12","volume":"10","author":"Wong","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B235","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/10430340150218396","article-title":"Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma","volume":"12","author":"Wong","year":"2001","journal-title":"Hum Gene Ther."},{"key":"B236","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.160.9.4457","article-title":"In situ cancer vaccination: an IL-12 defective vector\/replication-competent herpes simplex virus combination induces local and systemic antitumor activity","volume":"160","author":"Toda","year":"1998","journal-title":"J Immunol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00002371-200403000-00002","article-title":"Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12","volume":"27","author":"Iizuka","year":"2004","journal-title":"J Immunother."},{"key":"B238","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13048-016-0282-3","article-title":"IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice","volume":"9","author":"Thomas","year":"2016","journal-title":"J Ovarian Res."},{"key":"B239","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omto.2017.09.003","article-title":"Newly characterized murine undifferentiated sarcoma models sensitive to virotherapy with oncolytic HSV-1 M002","volume":"7","author":"Ring","year":"2017","journal-title":"Mol Ther Oncolytics."},{"key":"B240","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.cgt.7700900","article-title":"Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers","volume":"13","author":"Varghese","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"B241","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.cgt.7701053","article-title":"Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms","volume":"14","author":"Derubertis","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"B242","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1073\/pnas.040557897","article-title":"Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors","volume":"97","author":"Parker","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B243","doi-asserted-by":"publisher","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B244","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1215\/S1152851705000074","article-title":"Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model","volume":"7","author":"Hellums","year":"2005","journal-title":"Neuro Oncol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"628697","DOI":"10.1155\/2012\/628697","article-title":"Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases","volume":"2012","author":"Cody","year":"2012","journal-title":"Int J Breast Cancer."},{"key":"B246","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1128\/JVI.06998-11","article-title":"Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12","volume":"86","author":"Markert","year":"2012","journal-title":"J Virol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"e1007209","DOI":"10.1371\/journal.ppat.1007209","article-title":"A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors","volume":"14","author":"Leoni","year":"2018","journal-title":"PLoS Pathog."},{"key":"B248","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1038\/s41388-019-0737-2","article-title":"Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model","volume":"38","author":"Alessandrini","year":"2019","journal-title":"Oncogene."},{"key":"B249","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/hum.2013.201","article-title":"Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates","volume":"25","author":"Roth","year":"2014","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B250","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1099\/0022-1317-80-9-2287","article-title":"The molecular pathogenesis of semliki forest virus: a model virus made useful?","volume":"80","author":"Atkins","year":"1999","journal-title":"J Gen Virol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ymthe.2005.02.011","article-title":"Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas","volume":"12","author":"Rodriguez-Madoz","year":"2005","journal-title":"Mol Ther."},{"key":"B252","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.3171\/foc.2000.9.6.8","article-title":"Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered semliki forest virus to produce interleukin-12","volume":"9","author":"Yamanaka","year":"2000","journal-title":"Neurosurg Focus."},{"key":"B253","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3171\/jns.2002.97.3.0611","article-title":"Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing semliki forest virus-mediated interleukin-12","volume":"97","author":"Yamanaka","year":"2002","journal-title":"J Neurosurg."},{"key":"B254","doi-asserted-by":"publisher","first-page":"12266","DOI":"10.1128\/JVI.01597-09","article-title":"Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma","volume":"83","author":"Rodriguez-Madoz","year":"2009","journal-title":"J Virol."},{"key":"B255","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1089\/hum.2013.080","article-title":"Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas","volume":"25","author":"Rodriguez-Madoz","year":"2014","journal-title":"Hum Gene Ther."},{"key":"B256","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12885-015-1618-x","article-title":"Neoadjuvant administration of semliki forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice","volume":"15","author":"Kramer","year":"2015","journal-title":"BMC Cancer."},{"key":"B257","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/sj.gt.3300841","article-title":"Transfer of the murine interleukin-12 gene in vivo by a semliki forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by doppler ultrasonography","volume":"6","author":"Asselin-Paturel","year":"1999","journal-title":"Gene Ther."},{"key":"B258","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00109-010-0620-7","article-title":"The anti-angiogenic activity of IL-12 is increased in iNOS-\/- mice and involves NK cells","volume":"88","author":"Bielawska-Pohl","year":"2010","journal-title":"J Mol Med."},{"key":"B259","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/0008-5472.CAN-13-3356","article-title":"Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12","volume":"75","author":"Melero","year":"2015","journal-title":"Cancer Res."},{"key":"B260","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ijc.10184","article-title":"Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression","volume":"98","author":"Colmenero","year":"2002","journal-title":"Int J Cancer."},{"key":"B261","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/mt.2012.56","article-title":"Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic semliki forest virus encoding IL-12","volume":"20","author":"Quetglas","year":"2012","journal-title":"Mol Ther."},{"key":"B262","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1158\/2326-6066.CIR-14-0216","article-title":"Virotherapy with a semliki forest virus-based vector encoding IL12 synergizes with PD-1\/PD-L1 blockade","volume":"3","author":"Quetglas","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B263","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/sj.gt.3302561","article-title":"Regression of mouse tumours and inhibition of metastases following administration of a semliki forest virus vector with enhanced expression of IL-12","volume":"12","author":"Chikkanna-Gowda","year":"2005","journal-title":"Gene Ther."},{"key":"B264","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2990.2010.01110.x","article-title":"Semliki forest virus-mediated gene therapy of the RG2 rat glioma","volume":"36","author":"Roche","year":"2010","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B265","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/00002371-200101000-00006","article-title":"Low-dose vaccinia virus-mediated cytokine gene therapy of glioma","volume":"24","author":"Chen","year":"2001","journal-title":"J Immunother."},{"key":"B266","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/cyto.2001.0906","article-title":"Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy","volume":"15","author":"Chen","year":"2001","journal-title":"Cytokine."},{"key":"B267","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/cgt.2009.85","article-title":"Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution","volume":"17","author":"Jackaman","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"B268","doi-asserted-by":"publisher","first-page":"eaax7992","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci Transl Med."},{"key":"B269","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1089\/10430349850019328","article-title":"Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity","volume":"9","author":"Puisieux","year":"1998","journal-title":"Hum Gene Ther."},{"key":"B270","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/hum.2005.16.91","article-title":"Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma","volume":"16","author":"Triozzi","year":"2005","journal-title":"Hum Gene Ther."},{"key":"B271","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1158\/1078-0432.CCR-04-2283","article-title":"Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma","volume":"11","author":"Triozzi","year":"2005","journal-title":"Clin Cancer Res."},{"key":"B272","doi-asserted-by":"publisher","first-page":"e1285992","DOI":"10.1080\/2162402X.2017.1285992","article-title":"Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation","volume":"6","author":"Veinalde","year":"2017","journal-title":"Oncoimmunology."},{"key":"B273","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/v11100914","article-title":"Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 agonists","volume":"11","author":"Backhaus","year":"2019","journal-title":"Viruses."},{"key":"B274","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/01.mlg.0000246194.66295.d8","article-title":"Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma","volume":"117","author":"Shin","year":"2007","journal-title":"Laryngoscope."},{"key":"B275","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/cgt.2009.41","article-title":"Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy","volume":"17","author":"Tsai","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"B276","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/0008-5472.CAN-05-0877","article-title":"Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector","volume":"66","author":"Guan","year":"2006","journal-title":"Cancer Res."},{"key":"B277","doi-asserted-by":"publisher","first-page":"e01677","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J Virol."},{"key":"B278","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/sj.cgt.7700309","article-title":"Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8+ T-cell immunity and NK activity","volume":"8","author":"Slos","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"B279","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.gt.3303037","article-title":"Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice","volume":"15","author":"Petry","year":"2008","journal-title":"Gene Ther."},{"key":"B280","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.gt.3300508","article-title":"Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination","volume":"4","author":"Bramson","year":"1997","journal-title":"Gene Ther."},{"key":"B281","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.gt.3301387","article-title":"Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12","volume":"8","author":"Mazzolini","year":"2001","journal-title":"Gene Ther."},{"key":"B282","first-page":"3625","article-title":"Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors","volume":"7","author":"Lohr","year":"2001","journal-title":"Clin Cancer Res."},{"key":"B283","first-page":"1233","article-title":"Systemic dissemination of viral vectors during intratumoral injection","volume":"2","author":"Wang","year":"2003","journal-title":"Mol Cancer Ther."},{"key":"B284","first-page":"11","article-title":"In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector","volume":"3","author":"Toloza","year":"1996","journal-title":"Cancer Gene Ther."},{"key":"B285","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front Oncol."},{"key":"B286","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1089\/104303402317322294","article-title":"Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver","volume":"13","author":"Sung","year":"2002","journal-title":"Hum Gene Ther."},{"key":"B287","doi-asserted-by":"publisher","first-page":"15006","DOI":"10.1038\/mto.2015.6","article-title":"Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer","volume":"2","author":"Freytag","year":"2015","journal-title":"Mol Ther Oncolytics."},{"key":"B288","first-page":"4035","article-title":"Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12","volume":"59","author":"Nishioka","year":"1999","journal-title":"Cancer Res."},{"key":"B289","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/sj.gt.3301010","article-title":"Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas","volume":"6","author":"Melero","year":"1999","journal-title":"Gene Ther."},{"key":"B290","first-page":"182","article-title":"Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo","volume":"54","author":"Tahara","year":"1994","journal-title":"Cancer Res"},{"key":"B291","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.155.3.1393","article-title":"Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts","volume":"155","author":"Zitvogel","year":"1995","journal-title":"J Immunol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/pcan.2008.57","article-title":"Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer","volume":"12","author":"Tabata","year":"2009","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B293","first-page":"7853","article-title":"Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model","volume":"63","author":"Satoh","year":"2003","journal-title":"Cancer Res."},{"key":"B294","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jnci\/89.14.1049","article-title":"Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12","volume":"89","author":"Cavallo","year":"1997","journal-title":"J Natl Cancer Inst."},{"key":"B295","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3171\/jns.2000.92.3.0419","article-title":"Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats","volume":"92","author":"DiMeco","year":"2000","journal-title":"J Neurosurg."},{"key":"B296","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/1759-7714.12151","article-title":"Expression of interleukin-12 by adipose-derived mesenchymal stem cells for treatment of lung adenocarcinoma","volume":"6","author":"Li","year":"2015","journal-title":"Thorac Cancer."},{"key":"B297","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2009.08.031","article-title":"Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma","volume":"290","author":"Gao","year":"2010","journal-title":"Cancer Lett."},{"key":"B298","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1600-0625.2006.00479.x","article-title":"Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model","volume":"15","author":"Elzaouk","year":"2006","journal-title":"Exp Dermatol."},{"key":"B299","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/sj.gt.3301353","article-title":"Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines","volume":"7","author":"Akiyama","year":"2000","journal-title":"Gene Ther."},{"key":"B300","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.cgt.7700709","article-title":"Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model","volume":"11","author":"Saika","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"B301","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1163\/156856209X434674","article-title":"Augmented anti-tumor effect of dendritic cells genetically engineered by interleukin-12 plasmid DNA","volume":"21","author":"Yoshida","year":"2010","journal-title":"J Biomater Sci Polym Ed."},{"key":"B302","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0301-472X(01)00792-5","article-title":"Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12","volume":"30","author":"Rodriguez-Calvillo","year":"2002","journal-title":"Exp Hematol."},{"key":"B303","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1053\/jpsu.2001.25796","article-title":"Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma","volume":"36","author":"Shimizu","year":"2001","journal-title":"J Pediatr Surg"},{"key":"B304","first-page":"6378","article-title":"Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity","volume":"63","author":"Tatsumi","year":"2003","journal-title":"Cancer Res."},{"key":"B305","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ymthe.2005.03.030","article-title":"Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells","volume":"12","author":"Vera","year":"2005","journal-title":"Mol Ther."},{"key":"B306","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/sj.gt.3302941","article-title":"Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity","volume":"14","author":"Tatsumi","year":"2007","journal-title":"Gene Ther."},{"key":"B307","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3892\/or.2019.7165","article-title":"Intratumoral injection of dendritic cells overexpressing interleukin12 inhibits melanoma growth","volume":"42","author":"Yao","year":"2019","journal-title":"Oncol Rep."},{"key":"B308","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/cgt.2009.33","article-title":"Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity","volume":"16","author":"Komita","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"B309","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00262-011-1198-9","article-title":"Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines","volume":"61","author":"Huang","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B310","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1200\/JCO.2005.00.463","article-title":"Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas","volume":"23","author":"Mazzolini","year":"2005","journal-title":"J Clin Oncol."},{"key":"B311","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3748\/wjg.v9.i5.951","article-title":"Continuous release of interleukin 12 from microencapsulated engineered cells for colon cancer therapy","volume":"9","author":"Zheng","year":"2003","journal-title":"World J Gastroenterol."},{"key":"B312","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1089\/104303401300057388","article-title":"Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study","volume":"12","author":"Kang","year":"2001","journal-title":"Hum Gene Ther."},{"key":"B313","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/stem.645","article-title":"Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems","volume":"29","author":"Reagan","year":"2011","journal-title":"Stem Cells."},{"key":"B314","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cncr.24013","article-title":"Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into ewing sarcoma tumors","volume":"115","author":"Duan","year":"2009","journal-title":"Cancer."},{"key":"B315","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1166\/jbn.2014.1712","article-title":"Reversal of tumor growth by gene modification of mesenchymal stem cells using spermine-pullulan\/DNA nanoparticles","volume":"10","author":"Hu","year":"2014","journal-title":"J Biomed Nanotechnol."},{"key":"B316","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2010.187","article-title":"Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells","volume":"22","author":"Ryu","year":"2011","journal-title":"Hum Gene Ther."},{"key":"B317","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3892\/etm.2014.1918","article-title":"Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice","volume":"8","author":"Han","year":"2014","journal-title":"Exp Ther Med."},{"key":"B318","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/gt.2010.170","article-title":"The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity","volume":"18","author":"Seo","year":"2011","journal-title":"Gene Ther."},{"key":"B319","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clim.2016.06.013","article-title":"Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells","volume":"177","author":"Goding","year":"2017","journal-title":"Clin Immunol."},{"key":"B320","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B321","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"B322","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther."},{"key":"B323","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood."},{"key":"B324","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol Ther Oncolytics."},{"key":"B325","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"B326","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J Immunol."},{"key":"B327","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1016\/j.vaccine.2007.10.037","article-title":"Chitosan solution enhances the immunoadjuvant properties of GM-CSF","volume":"25","author":"Zaharoff","year":"2007","journal-title":"Vaccine."},{"key":"B328","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/ijerph16122153","article-title":"Sustained release technology and its application in environmental remediation: a review","volume":"16","author":"Wang","year":"2019","journal-title":"Int J Environ Res Public Health."},{"key":"B329","doi-asserted-by":"publisher","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat Rev Mater."},{"key":"B330","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1039\/C3TB21016B","article-title":"Recent advances in hydrogel based drug delivery systems for the human body","volume":"2","author":"Vashist","year":"2014","journal-title":"J Mater Chem B."},{"key":"B331","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1067\/msy.2001.115839","article-title":"Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases","volume":"130","author":"Sabel","year":"2001","journal-title":"Surgery."},{"key":"B332","first-page":"3832","article-title":"In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity","volume":"60","author":"Egilmez","year":"2000","journal-title":"Cancer Res."},{"key":"B333","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00002371-200003000-00003","article-title":"Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model","volume":"23","author":"Egilmez","year":"2000","journal-title":"J Immunother."},{"key":"B334","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.surg.2007.05.008","article-title":"Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells","volume":"142","author":"Sabel","year":"2007","journal-title":"Surgery."},{"key":"B335","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-009-0570-3","article-title":"Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer","volume":"122","author":"Sabel","year":"2010","journal-title":"Breast Cancer Res Treat."},{"key":"B336","first-page":"2937","article-title":"Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice","volume":"57","author":"Iwanuma","year":"1997","journal-title":"Cancer Res."},{"key":"B337","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/(SICI)1097-0347(200001)22:1<57::AID-HED9>3.0.CO;2-K","article-title":"Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft\/SCID mouse model","volume":"22","author":"Kuriakose","year":"2000","journal-title":"Head Neck."},{"key":"B338","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4049\/jimmunol.170.1.400","article-title":"Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma","volume":"170","author":"Hess","year":"2003","journal-title":"J Immunol."},{"key":"B339","doi-asserted-by":"publisher","first-page":"898","DOI":"10.4049\/jimmunol.174.2.898","article-title":"Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells","volume":"174","author":"Broderick","year":"2005","journal-title":"J Immunol."},{"key":"B340","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00262-007-0430-0","article-title":"Transient activation of tumor-associated T-effector\/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease","volume":"57","author":"Gu","year":"2008","journal-title":"Cancer Immunol Immunother."},{"key":"B341","first-page":"7254","article-title":"Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease","volume":"62","author":"Hill","year":"2002","journal-title":"Cancer Res."},{"key":"B342","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4049\/jimmunol.1100168","article-title":"Dichotomous effects of IFN-gamma on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity","volume":"187","author":"Harden","year":"2011","journal-title":"J Immunol."},{"key":"B343","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.4049\/jimmunol.0802793","article-title":"Central role of tumor-associated CD8+ T effector\/memory cells in restoring systemic antitumor immunity","volume":"182","author":"Kilinc","year":"2009","journal-title":"J Immunol."},{"key":"B344","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.4049\/jimmunol.0902625","article-title":"Activated CD8+ T-effector\/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis","volume":"183","author":"Kilinc","year":"2009","journal-title":"J Immunol."},{"key":"B345","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1158\/0008-5472.CAN-09-3170","article-title":"Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity","volume":"70","author":"Gu","year":"2010","journal-title":"Cancer Res."},{"key":"B346","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1002\/eji.200839010","article-title":"Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression","volume":"39","author":"Watkins","year":"2009","journal-title":"Eur J Immunol."},{"key":"B347","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1245\/ASO.2004.03.022","article-title":"Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity","volume":"11","author":"Sabel","year":"2004","journal-title":"Ann Surg Oncol."},{"key":"B348","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CJI.0b013e318156e6a7","article-title":"Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres","volume":"30","author":"Sabel","year":"2007","journal-title":"J Immunother."},{"key":"B349","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.cji.0000175489.19314.d2","article-title":"IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2\/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity","volume":"29","author":"Nair","year":"2006","journal-title":"J Immunother."},{"key":"B350","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.4049\/jimmunol.176.12.7325","article-title":"Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2\/neu transgenic mice bearing advanced spontaneous tumors","volume":"176","author":"Nair","year":"2006","journal-title":"J Immunol."},{"key":"B351","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.4049\/jimmunol.1101136","article-title":"Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation","volume":"187","author":"Rowswell-Turner","year":"2011","journal-title":"J Immunol."},{"key":"B352","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4161\/onci.19369","article-title":"Chemoimmunotherapy as long-term maintenance therapy for cancer","volume":"1","author":"Egilmez","year":"2012","journal-title":"Oncoimmunology."},{"key":"B353","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.celrep.2019.08.095","article-title":"Stereotactic body radiation and interleukin-12 combination therapy eradicates pancreatic tumors by repolarizing the immune microenvironment","volume":"29","author":"Mills","year":"2019","journal-title":"Cell Rep."},{"key":"B354","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/md14050091","article-title":"Effect of chitosan properties on immunoreactivity","volume":"14","author":"Ravindranathan","year":"2016","journal-title":"Mar Drugs."},{"key":"B355","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-09-1114","article-title":"Intravesical immunotherapy of superficial bladder cancer with chitosan\/interleukin-12","volume":"69","author":"Zaharoff","year":"2009","journal-title":"Cancer Res."},{"key":"B356","first-page":"867","article-title":"Characterization of a sustained-release delivery system for combined cytokine\/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix","volume":"3","author":"Cole","year":"1997","journal-title":"Clin Cancer Res."},{"key":"B357","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/00002371-200109000-00004","article-title":"Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response","volume":"24","author":"Nguyen","year":"2001","journal-title":"J Immunother."},{"key":"B358","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.4049\/jimmunol.172.9.5159","article-title":"Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine","volume":"172","author":"Salem","year":"2004","journal-title":"J Immunol."},{"key":"B359","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/01.cji.0000170361.37832.ec","article-title":"Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model","volume":"28","author":"van Bruggen","year":"2005","journal-title":"J Immunother."},{"key":"B360","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3855\/jidc.541","article-title":"Using poly-N-acetyl glucosamine gel matrix to deliver IL-12 with anti-schistosomasis vaccination","volume":"4","author":"Salem","year":"2010","journal-title":"J Infect Dev Ctries."},{"key":"B361","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/jbm.1270","article-title":"Evaluation of the biocompatibility of a chitosan scaffold in mice","volume":"59","author":"VandeVord","year":"2002","journal-title":"J Biomed Mater Res."},{"key":"B362","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jbm.a.31256","article-title":"Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat","volume":"83","author":"Azab","year":"2007","journal-title":"J Biomed Mater Res A."},{"key":"B363","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.clim.2009.03.516","article-title":"IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments","volume":"132","author":"Simpson-Abelson","year":"2009","journal-title":"Clin Immunol."},{"key":"B364","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1021\/mp5002697","article-title":"Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer","volume":"11","author":"Meraz","year":"2014","journal-title":"Mol Pharm."},{"key":"B365","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s002620050455","article-title":"Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft\/SCID mouse model","volume":"46","author":"Egilmez","year":"1998","journal-title":"Cancer Immunol Immunother."},{"key":"B366","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1089\/cbr.2004.19.764","article-title":"Characterization of cytokine-encapsulated controlled-release microsphere adjuvants","volume":"19","author":"Sharma","year":"2004","journal-title":"Cancer Biother Radiopharm."},{"key":"B367","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/71916","article-title":"Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)","volume":"18","author":"Zhu","year":"2000","journal-title":"Nat Biotechnol."},{"key":"B368","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0928-0987(03)00019-8","article-title":"Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha","volume":"18","author":"Sanchez","year":"2003","journal-title":"Eur J Pharm Sci."},{"key":"B369","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J."},{"key":"B370","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front Pharmacol."},{"key":"B371","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for cancer: a trigger for metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res."},{"key":"B372","doi-asserted-by":"publisher","first-page":"110733","DOI":"10.18632\/oncotarget.22717","article-title":"Chemotherapy-induced metastasis in breast cancer","volume":"8","author":"Karagiannis","year":"2017","journal-title":"Oncotarget."},{"key":"B373","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41368-020-00087-0","article-title":"Radiotherapy targeting cancer stem cells awakens them to induce tumour relapse and metastasis in oral cancer","volume":"12","author":"Liu","year":"2020","journal-title":"Int J Oral Sci."},{"key":"B374","first-page":"2434","article-title":"Biological behavior of human breast cancer micrometastases","volume":"7","author":"Klauber-DeMore","year":"2001","journal-title":"Clin Cancer Res."},{"key":"B375","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1158\/1078-0432.CCR-09-1861","article-title":"A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice","volume":"15","author":"Malvicini","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B376","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med."},{"key":"B377","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-11-3538","article-title":"The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor","volume":"72","author":"Abastado","year":"2012","journal-title":"Cancer Res."},{"key":"B378","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1158\/0008-5472.CAN-11-1466","article-title":"Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control","volume":"71","author":"Hong","year":"2011","journal-title":"Cancer Res."},{"key":"B379","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis."},{"key":"B380","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fonc.2012.00191","article-title":"Radiation-induced effects and the immune system in cancer","volume":"2","author":"Kaur","year":"2012","journal-title":"Front Oncol."},{"key":"B381","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1269\/jrr.10185","article-title":"A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma","volume":"52","author":"Kim","year":"2011","journal-title":"J Radiat Res."},{"key":"B382","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ijc.29428","article-title":"Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma","volume":"137","author":"Jeong","year":"2015","journal-title":"Int J Cancer."},{"key":"B383","doi-asserted-by":"publisher","first-page":"e1477459","DOI":"10.1080\/2162402X.2018.1477459","article-title":"Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment","volume":"7","author":"Wu","year":"2018","journal-title":"Oncoimmunology."},{"key":"B384","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1080\/00365521.2017.1346705","article-title":"The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy","volume":"52","author":"Ansari","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"B385","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat Commun."},{"key":"B386","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1245\/s10434-019-07261-7","article-title":"Systematic review of surgical and percutaneous irreversible electroporation in the treatment of locally advanced pancreatic cancer","volume":"26","author":"Moris","year":"2019","journal-title":"Ann Surg Oncol."},{"key":"B387","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ebiom.2019.05.036","article-title":"High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity","volume":"44","author":"Ringel-Scaia","year":"2019","journal-title":"EBioMedicine."},{"key":"B388","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10549-004-3289-1","article-title":"Immunologic response to cryoablation of breast cancer","volume":"90","author":"Sabel","year":"2005","journal-title":"Breast Cancer Res Treat."},{"key":"B389","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","article-title":"Thermal ablation of tumours: biological mechanisms and advances in therapy","volume":"14","author":"Chu","year":"2014","journal-title":"Nat Rev Cancer."},{"key":"B390","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1158\/0008-5472.CAN-06-0206","article-title":"Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine","volume":"66","author":"den Brok","year":"2006","journal-title":"Cancer Res."},{"key":"B391","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.amjsurg.2009.12.025","article-title":"Changes in interleukin-1beta and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections","volume":"200","author":"Ahmad","year":"2010","journal-title":"Am J Surg."},{"key":"B392","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jvir.2013.02.015","article-title":"Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10","volume":"24","author":"Erinjeri","year":"2013","journal-title":"J Vasc Interv Radiol."},{"key":"B393","doi-asserted-by":"publisher","first-page":"e1326441","DOI":"10.1080\/2162402X.2017.1326441","article-title":"Characterization of the cryoablation-induced immune response in kidney cancer patients","volume":"6","author":"Kato","year":"2017","journal-title":"Oncoimmunology."},{"key":"B394","article-title":"Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12","volume-title":"34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): Part 2","author":"Vrabel","year":"2019"},{"key":"B395","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1002\/ijc.32603","article-title":"The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors","volume":"146","author":"Puca","year":"2020","journal-title":"Int J Cancer."},{"key":"B396","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1084\/jem.20130678","article-title":"Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection","volume":"210","author":"Vom Berg","year":"2013","journal-title":"J Exp Med."},{"key":"B397","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B398","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1158\/1078-0432.CCR-18-0381","article-title":"Revisiting interleukin-12 as a cancer immunotherapy agent","volume":"24","author":"Berraondo","year":"2018","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.575597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:17:42Z","timestamp":1696882662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.575597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":398,"alternative-id":["10.3389\/fimmu.2020.575597"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.575597","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"article-number":"575597"}}